newsfilter
← Latest News
Earnings Call Transcripts·

Inhibikase Therapeutics, Inc. at Jefferies Global Healthcare Conference in London - INHIBIKASE THERAPEUTICS INC

  • Explicit Guidance:

    • Clinical Data Timelines:
      • Mid-2027: Disclosure of a safety update based on 50 patients and 12 weeks of data to satisfy a financing tranche obligation; disclosure limited to DSMB confirmation that the trial can continue without meaningful safety issues.
      • Mid-2028: Readout of Part A data (140 patients) with the primary endpoint of Pulmonary Vascular Resistance (PVR); includes six-minute walk distance and other secondary endpoint data.
      • Mid-2029: Pivotal data readout (Part B) to support NDA filing.
    • Corporate Lifespan & Capital:
      • Runway: Sufficient cash runway to complete the trial program through mid-2029.
      • Intellectual Property: Core patent protection through 2039; use patents extending to 2044.
      • Strategic Efficiency: Utilization of the 505(b)(2) regulatory pathway, estimated to shave three years off the time to NDA/approval compared to a traditional sequential Phase 2b/Phase 3 program.
    • Dose & Efficacy Targets:
      • Target Doses: Aims for patient titration up to 500 mg (approx. equivalent to 400 mg reference dose); expects lower doses (300 mg) to remain viable for the majority of patients.
      • Efficacy Expectations: Hopes to replicate IMPRESS-level efficacy (30% reduction in PVR, 30m improvement in six-minute walk); considers a 20% PVR reduction and 20m walk improvement as "clinically meaningful" and sufficient for product viability.
  • Business-Segment Outlook:

    • Product Positioning (PAH):
      • Treatment Paradigm Shift: Anticipates a transition where antiproliferatives (specifically the company's IKT001) become second-line therapy and eventually part of the starting regimen for difficult-to-treat patients over a 5–7 year horizon.
      • Combination Strategy: Expects routine use in combination with other antiproliferatives and existing vasodilators; early data suggests potential synergy with sotatercept.
      • Differentiation: Focus on "oral once-daily" utility and improved safety/tolerability (specifically GI profile) compared to competitor sotatercept and historical imatinib data.
    • Indication Expansion:
      • Preclinical Expansion: Plans to conduct preclinical studies in Group 2 and Group 3 Pulmonary Hypertension during 2027 to assess mechanism applicability.
    • Development Status:
      • Current Footprint: Phase 3 program active in 28 countries with 79 sites operational as of the past 4–6 months; execution described as meeting internal expectations.
  • Market and Competitive Outlook:

    • Competitive Landscape:
      • Competitor NDA: Observes a competitor's recent NDA filing; views regulatory acceptance/approval by a competitor as a potential "win-win" that could widen the FDA's confidence interval for similar data sets, though the company aims to establish a "number two" position with a potentially superior clinical profile.
      • Market Need: Forecasts a definitive need for multiple antiproliferative agents; believes no single drug will suffice for the disease course.
    • Demand Trends:
      • Early Treatment: Anticipates thought leaders shifting usage of antiproliferatives earlier in the disease course, moving away from late-line vasodilator reliance.
      • Clinical Utility: Identifies oral dosing (once daily) as a major competitive advantage over current injectable or complex regimens.
    • Safety Perception:
      • Edema Management: Anticipates improved safety profile perception due to better investigator training and protocol definitions distinguishing drug-induced edema from disease worsening, addressing a historical failure point in the IMPRESS trial.
  • Macro / Industry Outlook:

    • Regulatory Environment:
      • FDA Confidence: Expects the regulatory framework to support antiproliferative data similar to previous approvals (e.g., >20% PVR reduction), though maintaining high expectations for class-leading results.
      • Investigator Consensus: Notes that the medical community has "caught up" with the MOA, improving the ability to manage side effects and define endpoints correctly compared to earlier eras.
  • Strategic Initiatives:

    • Product Optimization: Implementation of a slow titration schedule (8-week ramp-up) to maximize tolerability and adherence to high doses (500 mg), contrasting with the 2-week titration in the IMPRESS trial.
    • Formulation Strategy: Launch of a pro-drug (IKT001) designed to remain intact in the GI tract to avoid C-kit inhibition in the gut, thereby reducing nausea/vomiting associated with standard imatinib.
    • Partnerships/Combinations: Continued exploration and dissemination of preclinical data supporting combination use with sotatercept.
  • Risks and Headwinds to Outlook:

    • Safety Risks: Potential for systemic side effects (e.g., edema) common to imatinib class; risk of patient dropouts if titration fails despite improved pro-drug formulation.
    • Data Limitations: The 2027 safety update is based on a small sample size (25 drug/25 placebo) and short duration (12 weeks), limiting statistical power and detailed disclosure.
    • Endpoint Variability: Six-minute walk test (6MWD) data in Part A (140 patients) is not powered for statistical significance and is subject to placebo response noise; Part B (340 patients) is the primary target for 6MWD significance.
    • Regulatory Uncertainty: Reliance on FDA acceptance of data sets similar to those used by competitors; potential delays or changes in endpoint interpretation.
  • Management Tone on the Future:

    • Confidence Level: High optimism ("super excited," "great place," "tremendous excitement") regarding the Phase 3 execution and the potential to become a new standard of care.
    • Hedges: Explicitly states that efficacy hopes are for 30% PVR reduction but defines 20% as a threshold for a "fantastic product"; acknowledges the 5–7 year timeline for the drug to potentially become part of starting regimens.
    • Comparison: Confidence in matching or exceeding the efficacy of sotatercept while offering superior oral utility and potentially a better tolerability profile.
  • Miscellaneous:

    • Financing: A $55 million financing tranche is tied directly to the 50-patient safety readout milestone.
    • Trial Design: Utilizes a split design (Part A and Part B) at the same sites to generate two independent data sets efficiently upon Part A completion.
Company
INHIBIKASE THERAPEUTICS INC
Keywords
INHIBIKASE THERAPEUTICS INC